

AMENDMENT

In the Claims:

Please replace the presently pending claims with the following claims:

*B1*  
1. (Amended) An immunogenic composition for eliciting an immune response to a pathogenic organism which composition comprises a recombinant protein and a polysaccharide component, wherein said protein is encoded by a gene from a strain of *Clostridium difficile* and said polysaccharide component is characteristic of a pathogenic microorganism, which pathogenic microorganism is other than *C. difficile*.

2. The immunogenic composition of claim 1, wherein said protein is a toxin or fragment thereof.

3. The immunogenic composition of claim 1, wherein said polysaccharide component is a capsular polysaccharide or a lipopolysaccharide.

4. (Amended) The immunogenic composition of claim 2, wherein said toxin is toxin A or a fragment thereof.

*P2*  
5. (Amended) The immunogenic composition of claim 4, wherein said toxin comprises a recombinant amino acid sequence that includes the toxin A repeating units (*rARU*) or a fragment thereof.

*P*  
6. (Amended) The immunogenic composition of claim 1, wherein said protein is a fusion protein.

7. (Amended) The immunogenic composition of claim 1, wherein said protein is toxin B or a fragment thereof.

8. (Amended) The immunogenic composition of claim 7, wherein said toxin comprises a recombinant amino acid sequence that includes the toxin B repeating units (*rBRU*) or a fragment thereof.

Please cancel claims 9-12.

13. (Amended) The immunogenic composition of claim 1, wherein said immune response comprises a cellular immune response.

B3  
14. (Amended) The immunogenic composition of claim 1, wherein said immune response comprises an immune response.

15. (Amended) The immunogenic composition of claim 1, wherein said immune response is protective against said pathogenic microorganism.

Please cancel claims 16-18.

19. (Amended) The immunogenic composition of claim 1, wherein said polysaccharide has been isolated from said pathogenic microorganism.

B4  
20. (Amended) The immunogenic composition of claim 1, wherein said pathogenic microorganism is selected from the group consisting of: *Streptococcus pneumoniae*; *Neisseria meningitidis*; *Escherichia coli*; and *Shigella*.

Please cancel claims 21-22.

23. (Amended) The immunogenic composition of claim 20, wherein said pathogenic microorganism is *Streptococcus pneumoniae*.

24. (Amended) The immunogenic composition of claim 23, wherein said immune response is protective against *Streptococcus pneumoniae*.

B5  
25. (Amended) The immunogenic composition of claim 20, wherein said pathogenic microorganism is *Shigella*.

26. (Amended) The immunogenic composition of claim 25, wherein said immune response is protective against *Shigella*.

Please cancel claim 27.

28. (Amended) The immunogenic composition of claim 20, wherein said pathogenic microorganism is *Neisseria meningitidis*.

29. (Amended) The immunogenic composition of claim 20, wherein said pathogenic microorganism is *Escherichia coli* K1.

B6  
30. (Amended) The immunogenic composition of claim 1, wherein said pathogenic microorganism is selected from the group consisting of: *Staphylococcus aureus*; coagulase-negative *Staphylococcus*; *Enterococcus* species; *Enterobacter* species; *Candida* species; and *Pseudomonas* species.

31. (Amended) The immunogenic composition of claim 30, wherein said immune response is protective with respect to *Staphylococcus aureus*; coagulase-negative *Staphylococcus*; *Enterococcus* species; *Enterobacter* species; *Candida* species; or *Pseudomonas* species.

Please cancel claim 32.

B7  
33. (Amended) The immunogenic composition of claim 30, wherein said pathogenic microorganism is *Staphylococcus aureus* serogroup 5 or serogroup 8.

Please cancel claims 34-35.

B8  
36. (Amended) The immunogenic composition of claim 1 which further comprises a pharmaceutically acceptable carrier.

37. A vaccine comprising the immunogenic composition of claim 36.

38. The vaccine of claim 37, wherein said vaccine is formulated for use in humans.

39. The vaccine of claim 37, wherein said vaccine is formulated for use in animals.

Please cancel claim 61.

Please add the following claims:

- 
62. (New) The immunogenic composition of claim 28, wherein said immune response is protective against *Neisseria meningitidis*.
63. (New) The immunogenic composition of claim 1, wherein said polysaccharide component is covalently coupled to said protein.
64. (New) A method to elicit an immune response in a subject to a pathogenic organism which method comprises administering to a subject in need of such response an effective amount of the immunogenic composition of claim 1.
65. (New) A method to elicit an immune response in a subject to a pathogenic organism which method comprises administering to a subject in need of such response an effective amount of the immunogenic composition of claim 36.
66. (New) A method to elicit an immune response in a subject to a pathogenic organism which method comprises administering to a subject in need of such response an effective amount of the vaccine of claim 37.